Literature DB >> 6813430

Enzymic differentiation of neurologic and nonneurologic forms of Gaucher's disease.

R H Glew, L B Daniels, L S Clark, S W Hoyer.   

Abstract

This study explores the biochemical basis that may distinguish neurologic and nonneurologic forms of Gaucher's disease. Crude membrane preparations from spleens of controls and patients representing the three clinical categories of Gaucher's disease were delipidated by extraction with sodium cholate and n-butanol. Total beta-glucosidase activity was estimated using 4-methylumbelliferyl-beta-D-glucopyranoside (MUG) as substrate, and glucocerebrosidase activity was determined using (3H)-glucocerebroside. beta-Glucosidase and glucocerebrosidase activities were reconstituted by inclusion of sodium taurocholate or phosphatidylserine in the assay medium. When assays contained phosphatidylserine, residual beta-glucosidase activity in delipidated spleen preparations from type 1, nonneurologic cases were five times greater than cases of neurologic Gaucher's disease (82.3 vs. 11.3 units per mg protein). However, beta-glucosidase assays using sodium taurocholate did not discriminate Gaucher's disease subtypes. Similar results were obtained when spleen preparations were analyzed for glucocerebrosidase using glucocerebroside as the substrate. Brain beta-glucosidase from patients representing the three classes of Gaucher's disease showed a similar pattern of sensitivity toward phosphatidylserine. The specific activity of beta-glucosidase in an extract of brain from the one case of type 1 Gaucher's disease analyzed was five times greater than the mean residual specific activity of brain beta-glucosidase measured in five cases of type 2 and type 3 Gaucher's disease. These findings suggest that, in patients with type 1 Gaucher's disease, glucocerebrosidase may show greater activity in the presence of acidic phospholipids than glucocerebrosidase does in patients with neurologic forms of the disease. The ability of the brain enzyme from a type 1 case to be profoundly stimulated by an acidic phospholipid may explain why such individuals are spared central nervous system involvement.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6813430     DOI: 10.1097/00005072-198211000-00006

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  8 in total

1.  Gaucher disease: the effects of phosphatidylserine on glucocerebrosidase from normal and Gaucher fibroblasts.

Authors:  F Y Choy
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

2.  Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.

Authors:  D Fabbro; R J Desnick; G A Grabowski
Journal:  Am J Hum Genet       Date:  1987-01       Impact factor: 11.025

3.  A kinetic study of the effects of galactocerebroside 3-sulphate on human spleen glucocerebrosidase. Evidence for two activator-binding sites.

Authors:  E M Prence; K O Garrett; R H Glew
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

4.  Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation.

Authors:  A Chabás; B Cormand; D Grinberg; J M Burguera; S Balcells; J L Merino; I Mate; J A Sobrino; R Gonzàlez-Duarte; L Vilageliu
Journal:  J Med Genet       Date:  1995-09       Impact factor: 6.318

5.  Gaucher disease (type 1): physical and kinetic properties of liposomal and soluble 'acid' beta-glucosidase.

Authors:  M Carroll
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

6.  Characterization of the phospholipid requirement of a rat liver beta-glucosidase.

Authors:  A Basu; R H Glew
Journal:  Biochem J       Date:  1984-12-01       Impact factor: 3.857

7.  Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site.

Authors:  T Dinur; K M Osiecki; G Legler; S Gatt; R J Desnick; G A Grabowski
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

Review 8.  Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.

Authors:  Daniel Ysselstein; Tiffany J Young; Maria Nguyen; Shalini Padmanabhan; Warren D Hirst; Nicolas Dzamko; Dimitri Krainc
Journal:  Mov Disord       Date:  2021-10-06       Impact factor: 9.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.